IL277127B2 - Use of pcsk9 inhibitor for reducing cardiovascular risk - Google Patents

Use of pcsk9 inhibitor for reducing cardiovascular risk

Info

Publication number
IL277127B2
IL277127B2 IL277127A IL27712720A IL277127B2 IL 277127 B2 IL277127 B2 IL 277127B2 IL 277127 A IL277127 A IL 277127A IL 27712720 A IL27712720 A IL 27712720A IL 277127 B2 IL277127 B2 IL 277127B2
Authority
IL
Israel
Prior art keywords
patient
risk
antigen
antibody
ldl
Prior art date
Application number
IL277127A
Other languages
English (en)
Hebrew (he)
Other versions
IL277127B1 (en
IL277127A (en
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of IL277127A publication Critical patent/IL277127A/en
Publication of IL277127B1 publication Critical patent/IL277127B1/en
Publication of IL277127B2 publication Critical patent/IL277127B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL277127A 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk IL277127B2 (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201862639407P 2018-03-06 2018-03-06
US201862640361P 2018-03-08 2018-03-08
US201862641082P 2018-03-09 2018-03-09
US201862641918P 2018-03-12 2018-03-12
US201862657495P 2018-04-13 2018-04-13
US201862683695P 2018-06-12 2018-06-12
US201862688622P 2018-06-22 2018-06-22
US201862717530P 2018-08-10 2018-08-10
US201862736284P 2018-09-25 2018-09-25
US201862744008P 2018-10-10 2018-10-10
US201862746319P 2018-10-16 2018-10-16
US201862770530P 2018-11-21 2018-11-21
US201862775219P 2018-12-04 2018-12-04
US201962797680P 2019-01-28 2019-01-28
US201962802545P 2019-02-07 2019-02-07
US201962806313P 2019-02-15 2019-02-15
EP19305247 2019-03-04
PCT/US2019/021034 WO2019173530A1 (en) 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk

Publications (3)

Publication Number Publication Date
IL277127A IL277127A (en) 2020-10-29
IL277127B1 IL277127B1 (en) 2025-07-01
IL277127B2 true IL277127B2 (en) 2025-11-01

Family

ID=66001316

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277127A IL277127B2 (en) 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk

Country Status (11)

Country Link
US (1) US20190292273A1 (https=)
EP (1) EP3762026B1 (https=)
JP (2) JP7426940B2 (https=)
KR (1) KR20200129127A (https=)
CN (1) CN113015543A (https=)
AU (1) AU2019231703A1 (https=)
CA (1) CA3092936A1 (https=)
IL (1) IL277127B2 (https=)
MX (1) MX2020009246A (https=)
TW (2) TW201945401A (https=)
WO (1) WO2019173530A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012052982A1 (en) 2010-10-22 2012-04-26 Neuravi Limited Clot engagement and removal system
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
ES3029850T3 (en) 2011-03-09 2025-06-25 Neuravi Ltd A clot retrieval device for removing occlusive clot from a blood vessel
US12076037B2 (en) 2011-03-09 2024-09-03 Neuravi Limited Systems and methods to restore perfusion to a vessel
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9433429B2 (en) 2013-03-14 2016-09-06 Neuravi Limited Clot retrieval devices
SI2967610T1 (sl) 2013-03-14 2019-07-31 Neuravi Limited Naprava za odkrivanje strdka za odstranjevanje okluzivnega strdka in krvne žile
EP2967611B1 (en) 2013-03-14 2019-01-16 Neuravi Limited Devices for removal of acute blockages from blood vessels
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
EP3223723B1 (en) 2014-11-26 2020-01-08 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
US10617435B2 (en) 2014-11-26 2020-04-14 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
KR102494176B1 (ko) 2016-09-06 2023-02-02 뉴라비 리미티드 혈관으로부터 폐색 혈전을 제거하기 위한 혈전 회수 장치
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
TWI759867B (zh) * 2019-09-19 2022-04-01 大陸商信達生物製藥（蘇州）有限公司 抗前蛋白轉化酶枯草桿菌蛋白酶／ｋｅｘｉｎ型９抗體用於製備治療膽固醇相關疾病之藥物的用途
US11712231B2 (en) 2019-10-29 2023-08-01 Neuravi Limited Proximal locking assembly design for dual stent mechanical thrombectomy device
US11517340B2 (en) 2019-12-03 2022-12-06 Neuravi Limited Stentriever devices for removing an occlusive clot from a vessel and methods thereof
US11717308B2 (en) 2020-04-17 2023-08-08 Neuravi Limited Clot retrieval device for removing heterogeneous clots from a blood vessel
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11730501B2 (en) 2020-04-17 2023-08-22 Neuravi Limited Floating clot retrieval device for removing clots from a blood vessel
US11737771B2 (en) 2020-06-18 2023-08-29 Neuravi Limited Dual channel thrombectomy device
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11864781B2 (en) 2020-09-23 2024-01-09 Neuravi Limited Rotating frame thrombectomy device
US11937837B2 (en) 2020-12-29 2024-03-26 Neuravi Limited Fibrin rich / soft clot mechanical thrombectomy device
US12029442B2 (en) 2021-01-14 2024-07-09 Neuravi Limited Systems and methods for a dual elongated member clot retrieval apparatus
US12064130B2 (en) 2021-03-18 2024-08-20 Neuravi Limited Vascular obstruction retrieval device having sliding cages pinch mechanism
US11974764B2 (en) 2021-06-04 2024-05-07 Neuravi Limited Self-orienting rotating stentriever pinching cells
CN115413625A (zh) * 2022-08-22 2022-12-02 郑咏秋 一种类风湿性冠心病动物模型及其构建方法和应用
CN118116596B (zh) * 2024-04-25 2024-07-02 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN121015868B (zh) * 2025-10-29 2026-03-20 核工业四一六医院 Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
NZ727849A (en) * 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
KR20220048051A (ko) * 2013-10-11 2022-04-19 사노피 바이오테크놀로지 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
RU2723018C2 (ru) 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAY, KAUSIK K., ET AL., REDUCTIONS IN ATHEROGENIC LIPIDS AND MAJOR CARDIOVASCULAR EVENTS: A POOLED ANALYSIS OF 10 ODYSSEY TRIALS COMPARING ALIROCUMAB WITH CONTROL., 13 December 2016 (2016-12-13) *

Also Published As

Publication number Publication date
JP2024028919A (ja) 2024-03-05
KR20200129127A (ko) 2020-11-17
EP3762026A1 (en) 2021-01-13
WO2019173530A1 (en) 2019-09-12
IL277127B1 (en) 2025-07-01
CA3092936A1 (en) 2019-09-12
TW202521589A (zh) 2025-06-01
US20190292273A1 (en) 2019-09-26
RU2020132463A (ru) 2022-04-06
TW201945401A (zh) 2019-12-01
IL277127A (en) 2020-10-29
MX2020009246A (es) 2021-01-15
JP7426940B2 (ja) 2024-02-02
AU2019231703A1 (en) 2020-10-22
JP2021515772A (ja) 2021-06-24
EP3762026B1 (en) 2026-04-08
CN113015543A (zh) 2021-06-22

Similar Documents

Publication Publication Date Title
EP3762026B1 (en) Use of pcsk9 inhibitor for reducing cardiovascular risk
US20220144969A1 (en) Methods for reducing cardiovascular risk
US20240261400A1 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
EP3068803B1 (en) Dosing regimens for use with pcsk9 inhibitors
RU2837845C2 (ru) Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1232890B (en) Methods for reducing cardiovascular risk
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis